Shin Poong Pharm.Co.,Ltd. (019170.KS)
KRW 10370.0
(-5.04%)
KRW 10370.0
(-5.04%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -57.32 Billion KRW | -62.35% |
| 2022 | -35.3 Billion KRW | -206.34% |
| 2021 | -11.52 Billion KRW | -330.39% |
| 2020 | 5 Billion KRW | -6.03% |
| 2019 | 5.32 Billion KRW | 89.88% |
| 2018 | 2.8 Billion KRW | 209.85% |
| 2017 | 904.88 Million KRW | 104.87% |
| 2016 | -18.59 Billion KRW | -1359.42% |
| 2015 | 1.47 Billion KRW | -55.93% |
| 2014 | 3.34 Billion KRW | -38.4% |
| 2013 | 5.43 Billion KRW | -62.18% |
| 2012 | 14.37 Billion KRW | -42.18% |
| 2011 | 24.86 Billion KRW | 14.41% |
| 2010 | 21.73 Billion KRW | 3.24% |
| 2009 | 21.05 Billion KRW | 74.69% |
| 2008 | 12.05 Billion KRW | 36.28% |
| 2007 | 8.84 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -52.72 Million KRW | 97.97% |
| 2024 Q1 | -2.59 Billion KRW | 92.19% |
| 2023 Q1 | -7.01 Billion KRW | 58.73% |
| 2023 Q2 | -8.99 Billion KRW | -28.27% |
| 2023 Q4 | -33.24 Billion KRW | -312.85% |
| 2023 Q3 | -8.05 Billion KRW | 10.52% |
| 2023 FY | -57.32 Billion KRW | -62.35% |
| 2022 Q2 | -4.57 Billion KRW | 13.65% |
| 2022 Q4 | -16.99 Billion KRW | -82.73% |
| 2022 FY | -35.3 Billion KRW | -206.34% |
| 2022 Q3 | -9.3 Billion KRW | -103.15% |
| 2022 Q1 | -5.3 Billion KRW | 53.66% |
| 2021 Q1 | 1.44 Billion KRW | 201.06% |
| 2021 Q2 | 389.81 Million KRW | -73.03% |
| 2021 Q3 | -1.97 Billion KRW | -606.05% |
| 2021 Q4 | -11.44 Billion KRW | -480.13% |
| 2021 FY | -11.52 Billion KRW | -330.39% |
| 2020 Q4 | 480.14 Million KRW | -52.18% |
| 2020 Q1 | 1.71 Billion KRW | 52.71% |
| 2020 FY | 5 Billion KRW | -6.03% |
| 2020 Q3 | 1 Billion KRW | -44.4% |
| 2020 Q2 | 1.8 Billion KRW | 5.46% |
| 2019 Q3 | 831.87 Million KRW | -65.86% |
| 2019 Q2 | 2.43 Billion KRW | 160.79% |
| 2019 Q1 | 934.2 Million KRW | 233.91% |
| 2019 Q4 | 1.12 Billion KRW | 34.81% |
| 2019 FY | 5.32 Billion KRW | 89.88% |
| 2018 Q4 | -697.64 Million KRW | -183.87% |
| 2018 FY | 2.8 Billion KRW | 209.85% |
| 2018 Q3 | 831.86 Million KRW | -53.53% |
| 2018 Q2 | 1.79 Billion KRW | 103.51% |
| 2018 Q1 | 879.54 Million KRW | 113.04% |
| 2017 Q2 | 3.45 Billion KRW | 166.55% |
| 2017 Q1 | 1.29 Billion KRW | 106.23% |
| 2017 FY | 904.88 Million KRW | 104.87% |
| 2017 Q4 | -6.74 Billion KRW | -332.31% |
| 2017 Q3 | 2.9 Billion KRW | -15.87% |
| 2016 Q3 | -359.18 Million KRW | -115.12% |
| 2016 Q4 | -20.78 Billion KRW | -5686.22% |
| 2016 Q1 | 175.28 Million KRW | -94.9% |
| 2016 FY | -18.59 Billion KRW | -1359.42% |
| 2016 Q2 | 2.37 Billion KRW | 1255.32% |
| 2015 FY | 1.47 Billion KRW | -55.93% |
| 2015 Q1 | -12.03 Million KRW | 99.37% |
| 2015 Q4 | 3.43 Billion KRW | 6639.84% |
| 2015 Q3 | 50.99 Million KRW | 102.55% |
| 2015 Q2 | -1.99 Billion KRW | -16512.58% |
| 2014 Q4 | -1.92 Billion KRW | -138.26% |
| 2014 Q1 | -3.78 Billion KRW | -201.51% |
| 2014 FY | 3.34 Billion KRW | -38.4% |
| 2014 Q2 | 4.03 Billion KRW | 206.56% |
| 2014 Q3 | 5.02 Billion KRW | 24.4% |
| 2013 Q2 | -7.5 Billion KRW | -208.08% |
| 2013 Q3 | 2.26 Billion KRW | 130.2% |
| 2013 Q4 | 3.73 Billion KRW | 64.76% |
| 2013 FY | 5.43 Billion KRW | -62.18% |
| 2013 Q1 | 6.94 Billion KRW | 532.35% |
| 2012 Q4 | -1.6 Billion KRW | -119.04% |
| 2012 FY | 14.37 Billion KRW | -42.18% |
| 2012 Q1 | 3.47 Billion KRW | 0.0% |
| 2012 Q2 | 2.59 Billion KRW | -25.37% |
| 2012 Q3 | 8.43 Billion KRW | 224.92% |
| 2011 Q2 | 6.99 Billion KRW | -16.83% |
| 2011 Q3 | 2.3 Billion KRW | -67.11% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 24.86 Billion KRW | 14.41% |
| 2011 Q1 | 8.41 Billion KRW | 0.0% |
| 2010 Q1 | 7.32 Billion KRW | 0.0% |
| 2010 FY | 21.73 Billion KRW | 3.24% |
| 2010 Q3 | 4.5 Billion KRW | -42.75% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 7.86 Billion KRW | 7.48% |
| 2009 Q1 | 2.58 Billion KRW | 0.0% |
| 2009 Q2 | 5.82 Billion KRW | 125.6% |
| 2009 Q3 | 7.16 Billion KRW | 23.0% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 21.05 Billion KRW | 74.69% |
| 2008 Q3 | 1.97 Billion KRW | -53.15% |
| 2008 Q1 | 3.17 Billion KRW | 0.0% |
| 2008 FY | 12.05 Billion KRW | 36.28% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 4.2 Billion KRW | 32.44% |
| 2007 Q3 | 1.49 Billion KRW | -57.68% |
| 2007 Q2 | 3.52 Billion KRW | 55.96% |
| 2007 Q1 | 2.25 Billion KRW | 0.0% |
| 2007 FY | 8.84 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -698.304% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 198.855% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 3.795% |
| HANDOK Inc. | -28.79 Billion KRW | -99.064% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | -581.213% |
| Yuhan Corporation | 93.5 Billion KRW | 161.304% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 615.402% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | -131.039% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 139.202% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 1733.85% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -2187.147% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -2664.122% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -1166.905% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 356.687% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -698.304% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | -173.749% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 1699.761% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 51.53% |
| JW Holdings Corporation | 19.02 Billion KRW | 401.296% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 27.37% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 126.974% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 254.907% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 1036.42% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 3545.989% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 1245.421% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -698.304% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 255.078% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 151.412% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 254.907% |
| Yuhan Corporation | 93.5 Billion KRW | 161.304% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | -252.777% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -1379.157% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 1036.808% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 254.907% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 403.216% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 218.78% |
| CKD Bio Corp. | -24.19 Billion KRW | -136.955% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 339.685% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 308.925% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 292.533% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | -0.0% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 221.949% |
| Boryung Corporation | 40.2 Billion KRW | 242.591% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | -82.975% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -2187.147% |
| JW Lifescience Corporation | 28.14 Billion KRW | 303.686% |